病例报告：低剂量白细胞介素-2：一种治疗由PD-1/PD-L1抑制剂引起的以毛囊周围水疱为主的大疱性类天疱疮的方法。
Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor.
作者信息
Zhang Yingyue, Cao Xianwei, Tong Jianbo
机构信息
Department of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Institute of Dermatology, Jiangxi Academy of Clinical Medical Sciences, Nanchang, China.
出版信息
Front Immunol. 2024 Dec 10;15:1496413. doi: 10.3389/fimmu.2024.1496413. eCollection 2024.
OBJECTIVES
This study aimed to evaluate the efficacy of low-dose interleukin (IL-2) treatment for bullous pemphigoid (BP) caused by anti-programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors.
METHODS
Low-dose IL-2 treatment was standardized for BP. The Bullous Pemphigoid Disease Area Index (BPDAI), 5D-Itch Scale (5D-IS), and Dermatology Life Quality Index (DLQI) were recorded before and after treatment, and hexachromatic lymphocytes, regulatory T cells (Treg cells), and cytokines were measured.
RESULTS
A significant decline in the BPDAI score, 5D-IS, and DLQI score was observed following treatment. The count of B-cells, CD4+ T-cells, CD8+ T-cells, Treg cells, and the levels of cytokines (IL-4, -8, and -10) were significantly downregulated in comparison to baseline measurements.
CONCLUSION
Low-dose IL-2 could be an effective therapeutic choice for treating BP caused by PD-1/PD-L1 inhibitors.
目的
本研究旨在评估低剂量白细胞介素（IL-2）治疗抗程序性细胞死亡蛋白1/配体1（PD-1/PD-L1）抑制剂所致大疱性类天疱疮（BP）的疗效。
方法
对BP患者的低剂量IL-2治疗进行标准化。记录治疗前后的大疱性类天疱疮疾病面积指数（BPDAI）、5D瘙痒量表（5D-IS）和皮肤病生活质量指数（DLQI），并检测六染色淋巴细胞、调节性T细胞（Treg细胞）和细胞因子。
结果
治疗后BPDAI评分、5D-IS和DLQI评分显著下降。与基线测量相比，B细胞、CD4+T细胞、CD8+T细胞、Treg细胞计数及细胞因子（IL-4、-8和-10）水平均显著下调。
结论
低剂量IL-2可能是治疗PD-1/PD-L1抑制剂所致BP的有效治疗选择。
Zotero 插件